Menu Search
Equities

Hikma Pharmaceuticals PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
HIK:LSE

Hikma Pharmaceuticals PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,577.00
  • Today's Change6.00 / 0.38%
  • Shares traded775.67k
  • 1 Year change-32.61%
  • Beta1.1690
Data delayed at least 20 minutes, as of Feb 13 2026 14:37 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Cash flow Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2024202420232022
OPERATIONS
Net income455281233
Depreciation/depletion90128372
Non-Cash items201117112
Cash taxes paid, supplemental12512955
Cash interest paid, supplemental848268
Changes in working capital(260)(49)(187)
Total cash from operations564608530
INVESTING
Capital expenditures(235)(204)(225)
Other investing and cash flow items, total(146)(129)(382)
Total cash from investing(381)(333)(607)
FINANCING
Financing cash flow items(78)(97)(77)
Total cash dividends paid(175)(137)(125)
Issuance (retirement) of stock, net(38)--(303)
Issuance (retirement) of debt, net103(103)447
Total cash from financing(188)(337)(58)
NET CHANGE IN CASH
Foreign exchange effects(12)(3)(21)
Net change in cash(17)(65)(156)
Net cash-begin balance/reserved for future use205270426
Net cash-end balance/reserved for future use188205270
SUPPLEMENTAL INCOME
Depreciation, supplemental90128372
Cash interest paid, supplemental848268
Cash taxes paid, supplemental12512955
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.